Advocacy
Make your voice heard. Learn about PDAB legislation and implementation processes across the country.
Legislation
Florida: HB 697 + SB 1158
Prescription Reduction Incentives and Competition Enhancement Act
– Implements international reference pricing of prescription drugs
– Implements certain PBM reforms
– Restricts mid-year health plan formulary changes
HB 697
12/9/25 – Introduced
12/16/25 – Referred to Health & Human Services and Budget Committees
12/16/25 – Assigned to Health Care Facilities & Systems Subcommittee
1/21/26 – Reported Favorably and sent to Budget Committee
1/27/26 – Reported Favorably and sent to Health and Human Services Committee
SB 1158
1/6/26 – Filed
1/12/26 – Referred to Health Policy, Appropriations Committee on Health & Human Services, Rules
Georgia: HB 931
Establishment of the Prescription Drug Affordability Board and Prescription Drug Cost Controls
1/12/26 – House Second Reading
Hawaii: SB 2933
Establishment of the Prescription Drug Affordability Board with authority to set upper payment limits.
1/23/26 – Introduced
1/26/26 – Passed First Reading
1/30/26 – Referred to HHS/CPN, WAM/JDC
Michigan: SB 3
Prescription Drug Cost and Affordability Review Act
Establishes a Prescription Drug Affordability Board.
1/8/25 – Introduced and Referred to Committee on Finance, Insurance, and Consumer Protection
4/24/25 – Reported Favorably with Substitute
4/24/25 – PASSED Senate: 20 YES – 15 NO
4/24/25 – Referred to House Committee on Government Operations
Rhode Island: S 2384
Implements price limits on prescription drugs referenced to Medicare’s maximum fair price.
1/30/26 – Introduced and Referred to Senate Health and Human Services Committee
Virginia: HB 483 + SB 271
Establishes a Prescription Drug Affordability Board and provides authority to set upper payment limits on prescription drugs.
HB 483
1/12/26 – Introduced and Referred to Committee on Labor and Commerce
1/19/26 – Assigned to Subcommittee #1
1/27/26 – Subcommittee #1 recommends reporting from full committee and referring to Appropriations Committee
1/29/26 – Scheduled for Committee hearing
SB 271
1/12/26 – Introduced and Referred to Committee on Education and Health
1/21/26 – Re-referred to Labor and Commerce Committee
1/26/26 – Reported from Labor and Commerce, sent to Finance and Appropriations Committee
West Virginia: HB 5149
Establishes a Prescription Drug Affordability Board and provides authority to set upper payment limits on prescription drugs.
2/3/26 – Introduced and Referred to Committees on Health and Human Services then Finance
Implementation
Colorado Prescription Drug Affordability Board
Next Regular Meeting: February 20, 2026 – 10AM MST
Previous Findings:
Trikafta – Not Unaffordable
Genvoya – Not Unaffordable
Enbrel – Unaffordable
Stelara – Unaffordable
Cosentyx – Unaffordable
In October 2025, the Board set an upper payment limit for Enbrel based on Medicare’s Maximum Fair Price. Rulemaking hearings for Stelara and Cosentyx are forthcoming.
Maine Prescription Drug Affordability Board
Next Regular Meeting: February 23, 2026 – 10:30 AM MST
In 2026, the Board will study upper payment limits and reference pricing, PBM reform, and other topics.
Maryland Prescription Drug Affordability Board
Next Regular Board Meeting: TBD
Informational Hearing: 2/10/26 – 1PM and 6PM EST
Topic: Cost review study process and policy review procedures
More Information HERE
At the May 2024 meeting, the PDAB selected six drugs for cost review:
Farxiga
Jardiance
Ozempic
Trulicity
Dupixent
Skyrizi
In July, 2025, the PDAB voted that Farxiga and Jardiance may cause affordability challenges. In November 2025, the PDAB voted that Ozempic and Trulicity may cause affordability challenges. Cost reviews for other selected drugs remain ongoing.
Minnesota Prescription Drug Affordability Board
Next Regular Board Meeting: February 10, 2026 – 9:00AM CST
Agenda TBD
Oregon Prescription Drug Affordability Board
Next Meeting: February 18, 2026 – 8AM PST
Register HERE
Agenda TBD
In June 2024, the board voted to pause current assessments in order to reevaluate their process and data, with assessments resuming in 2025. In March 2025, the PDAB selected 27 drugs to review. In June 2025, the list was narrowed to 23 drugs. It plans to review five or more drugs each month July through October, but has extended the deadline to publish its final report on affordability for the drugs to March 2026.
2025 Findings (Jan ’26):
Drugs that may cause affordability challenges:
Vraylar
Cosentyx
Trulicity
2024 Findings:
Ozempic – May Cause Affordability Challenges (2/21)
Trulicity – May Cause Affordability Challenges (2/21)
Shingrix- Reviewed, No Motion to Add to List of Drugs That May Cause Affordability Challenges (2/21)
Inflectra – Removed from Affordability Review (5/15)
Skyrizi – Removed from Affordability Review (5/15)
Washington Prescription Drug Affordability Board
Next Meeting: March 18, 2026 – 8:30AM PST
Agenda TBD
During its July 2025 meeting, the PDAB selected four drugs for cost review:
Enbrel
Xtandi
Cabometyx
Humira
© 2024 Value of Care Coalition
Washington, DC 20006